Magnets for Sale

neodymium cube Arial, Helvetica, sans-serif;”>This document contains forward-looking statements within the meaning of the Private Securities Litigation magnets for saleReform Act of 1995 and federal securities laws. Any statements contained in this press release that do not describe historical facts, neodymium cubeincluding but not limited to, statements regarding the safety of ferumoxytol as an iron replacement therapeutic, the benefits we receive from the role of the Scientific Advisory Board and the Data Monitoring ferrofluid Committee, our belief in the potential of ferumoxytol as an IV iron replacement <a herapeutic, and our ability to successfully complete development of and obtain FDA approvalmagnets for sale for ferumoxytol, are forward-looking statements that involve risks and uncertainties that could cause actual results to differ materially from those discussed in such forward-looking statements. Such risks and uncertainties include the following: (1) the possibilitymagnets for sale that we may not be able to successfully complete the clinical development of ferumoxytol, one ofneodymium cube our two products currently under development, or


may not be able to complete the development in a timelyneodymium cube or cost-effective manner, due to the timing of enrollment of patients in the Phase III neodymium cubestudies, unexpected results from our clinical sites, inadequate performance by third-party service providers involved in the magnets for saleconduct of the clinical trials, deficiencies in the design or oversight by us of these trials, or any other factor causing an increase in expenses, a delay and/or a negative effect on the results of the clinical studies for ferumoxytol;